Melanotan I

Synthetic analog of α-MSH that selectively targets MC1 receptors for melanin stimulation. FDA-approved as SCENESSE implant for erythropoietic protoporphyria (EPP). Research-grade injectable form enables flexible dosing versus the implant version.

Overview

Melanotan I (afamelanotide, CUV1647) is a synthetic tridecapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH) developed at the University of Arizona in the 1980s by Victor Hruby and colleagues. Unlike the native alpha-MSH (which is rapidly degraded in vivo with a half-life of minutes), Melanotan I incorporates a norleucine substitution at position 4 that confers resistance to enzymatic degradation, extending its biological activity. The peptide selectively activates melanocortin-1 receptors (MC1R) on epidermal melanocytes, stimulating eumelanin production and transfer to surrounding keratinocytes — effectively producing a natural tan without UV exposure. This mechanism provides genuine photoprotection by increasing the skin's melanin-based UV absorption capacity.

The clinical development of Melanotan I has been most advanced for erythropoietic protoporphyria (EPP), a rare genetic disorder in which deficient ferrochelatase activity leads to accumulation of protoporphyrin IX, causing severe phototoxicity and an inability to tolerate even brief sun exposure. Marketed under the brand name Scenesse (afamelanotide), the drug was approved by the European Medicines Agency (EMA) in 2014 and the FDA in 2019 as the first pharmacological treatment for EPP. Clinical trials demonstrated significant increases in pain-free sun exposure time, improved quality of life, and increased melanin density. The drug is administered as a subcutaneous biodegradable implant delivering 16 mg of afamelanotide over approximately 10 days, with treatments given every two months during periods of sun exposure.

Melanotan I is pharmacologically distinct from Melanotan II, which is a shorter cyclic heptapeptide that non-selectively activates multiple melanocortin receptors (MC1R, MC3R, MC4R, MC5R), producing not only tanning but also appetite suppression, erectile effects, and other systemic actions. Melanotan I's selectivity for MC1R limits its effect profile primarily to melanogenesis, resulting in a more predictable safety profile. Research has also explored Melanotan I for prevention of UV-induced skin damage and non-melanoma skin cancers in fair-skinned populations, with preclinical data showing reduced UV-induced DNA damage in melanized skin. Common side effects include nausea, facial flushing, and fatigue following implant placement, with darkening of existing nevi warranting dermatological monitoring.

Mechanism of Action

Melanotan I (afamelanotide) is a synthetic linear tridecapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH) with a [Nle4, D-Phe7] substitution that confers enhanced potency and metabolic stability. It acts as a selective agonist of the melanocortin 1 receptor (MC1R), a Gs protein-coupled receptor expressed predominantly on melanocytes in the basal layer of the epidermis. Upon binding MC1R, afamelanotide activates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP) levels and activating protein kinase A (PKA). PKA phosphorylates CREB (cAMP response element-binding protein), which translocates to the nucleus and drives transcription of the MITF (microphthalmia-associated transcription factor) gene.

MITF is the master regulator of melanogenesis, activating transcription of tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1), and dopachrome tautomerase (DCT/TYRP2)—the three key enzymes in the melanin biosynthetic pathway. This upregulation shifts melanin production toward eumelanin (brown-black pigment) rather than pheomelanin (red-yellow pigment), providing superior photoprotection through more efficient UV absorption and reduced generation of reactive oxygen species. The eumelanin-enriched melanosomes are transferred to surrounding keratinocytes via dendritic processes, creating a supranuclear melanin cap that shields keratinocyte DNA from UV-induced damage.

Beyond pigmentation, MC1R activation by afamelanotide stimulates anti-inflammatory signaling by suppressing NF-kB-mediated cytokine production and enhancing nucleotide excision repair (NER) of UV-induced cyclobutane pyrimidine dimers in an independent, non-pigmentary photoprotective pathway. These mechanisms underlie its approved therapeutic use in erythropoietic protoporphyria (EPP) and investigational applications in photodermatoses and skin cancer prevention.

Reconstitution Calculator

Safety Profile

Common side effects include nausea, headache, and skin darkening, particularly at the implant site. Regular full-body skin examinations are recommended to monitor for any new or changing moles, as the drug stimulates melanin production. It should be used only under medical supervision.

Pharmacokinetic Profile